This useful study provides incomplete evidence that TANGO2 homologs, including HRG-9 and HRG-10, are not heme chaperones but play a role in cellular bioenergetics and oxidative stress homeostasis.

Natural gas futures, which closed at ₹356.80/mmBtu last week, has largely been charting a sideways trend so far this week. It has been oscillating between ₹345 and ₹367. That said, the ...

The Delhi Metro Rail Corporation (DMRC) completed the tunnelling of the entire underground stretch of the Golden Line, being constructed under the Phase 4 expansion project. Listen to Story The boring ...

also known as the Golden Line, as per a post on X by the DMRC. DMRC MARKS HISTORIC TUNNEL BREAKTHROUGH AT IGNOU STATION; COMPLETES TUNNELLING WORK ON PHASE 4’S DEEPEST STRETCH The Delhi Metro ...

The Delhi Metro Rail Corporation (DMRC) Tuesday completed tunnelling on the deepest underground stretch of Phase 4 with a tunnel breakthrough at the IGNOU station on the Aerocity-Tughlakabad corridor, ...

Credit: SciTechDaily.com Physicists at Washington University have forged ahead in the field of quantum mechanics by creating a new phase of matter known as “time crystals” and the even more advanced ...

Thus, ABCA1, FLNA, LRP6, and SOX2 are promising targets for drug development. R3R-01 (also named R3R01, RG-7273) is a specific ABCA1 agonist and entered into phase 2 clinical trials by River 3 Renal ...

2003; Valiakhmetov et al., 2019). During SICD, exponential and stationary phase yeast cells undergo different cell death phenotypes. The markers of cell death are discussed below and summarized in ...

Louis have created a new type of "time crystal," a novel phase of matter that defies common perceptions of motion and time. The WashU research team includes Kater Murch, the Charles M. Hohenberg ...

following the pronouncement of Cebu City Mayor Raymond Garcia to include the purchase of Phase 3 in the 2025 annual budget. The council then approved a request for the Commission on Audit (COA) to ...

Pfizer and Arvinas’ estrogen receptor (ER) degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a subpopulation to suggest the therapy ...